Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential


Altinoz M. A. , Guloksuz S., Elmaci I.

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.19, sa.7, ss.785-792, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Konu: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s12094-017-1613-6
  • Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
  • Sayfa Sayıları: ss.785-792

Özet

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.